280 related articles for article (PubMed ID: 25267341)
1. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.
Wu CY; Chen DY; Shen JL; Ho HJ; Chen CC; Kuo KN; Liu HN; Chang YT; Chen YJ
Arthritis Res Ther; 2014 Sep; 16(5):449. PubMed ID: 25267341
[TBL] [Abstract][Full Text] [Related]
2. Infection risk in patients with rheumatoid arthritis treated with etanercept or adalimumab.
Chiang YC; Kuo LN; Yen YH; Tang CH; Chen HY
Comput Methods Programs Biomed; 2014 Oct; 116(3):319-27. PubMed ID: 25022467
[TBL] [Abstract][Full Text] [Related]
3. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer LK; Lunt M; Low AL; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2015 Jun; 74(6):1087-93. PubMed ID: 24685910
[TBL] [Abstract][Full Text] [Related]
4. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
6. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
Ann Rheum Dis; 2015 Jun; 74(6):1065-71. PubMed ID: 24608404
[TBL] [Abstract][Full Text] [Related]
7. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
Davies R; Galloway JB; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2011 Oct; 70(10):1831-4. PubMed ID: 21784722
[TBL] [Abstract][Full Text] [Related]
8. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Harrison MJ; Dixon WG; Watson KD; King Y; Groves R; Hyrich KL; Symmons DP; ;
Ann Rheum Dis; 2009 Feb; 68(2):209-15. PubMed ID: 18385277
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
10. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
[TBL] [Abstract][Full Text] [Related]
12. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
Neovius M; Arkema EV; Olsson H; Eriksson JK; Kristensen LE; Simard JF; Askling J;
Ann Rheum Dis; 2015 Feb; 74(2):354-60. PubMed ID: 24285495
[TBL] [Abstract][Full Text] [Related]
13. Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.
Desai RJ; Solomon DH; Schneeweiss S; Danaei G; Liao KP; Kim SC
Epidemiology; 2016 May; 27(3):414-22. PubMed ID: 26808597
[TBL] [Abstract][Full Text] [Related]
14. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
15. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
16. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
17. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.
Solomon DH; Curtis JR; Saag KG; Lii J; Chen L; Harrold LR; Herrinton LJ; Graham DJ; Kowal MK; Kuriya B; Liu L; Griffin MR; Lewis JD; Rassen JA
Am J Med; 2013 Aug; 126(8):730.e9-730.e17. PubMed ID: 23885678
[TBL] [Abstract][Full Text] [Related]
19. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials.
Liu Y; Fan W; Chen H; Yu MX
Asian Pac J Cancer Prev; 2014; 15(8):3403-10. PubMed ID: 24870729
[TBL] [Abstract][Full Text] [Related]
20. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
Arkema EV; Jonsson J; Baecklund E; Bruchfeld J; Feltelius N; Askling J;
Ann Rheum Dis; 2015 Jun; 74(6):1212-7. PubMed ID: 24608401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
